Correction

doi:10.2215/CJN.02810319

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Edwards ME, Chebib FT, Irazabal MV, Ofstie TG, Bungum LA, Metzger AJ, Senum SR, Hogan MC, El-Zoghby ZM, Kline TL, Harris PC, Czerwiec FS, Torres VE. Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 13: 1153–1161, 2018.

Because of author error, a correction has been issued for the above referenced article. The authors and editors have determined that the disclosures provided by Ziad M. El-Zoghby, Peter C. Harris, Marie C. Hogan, Sarah R. Senum, and Vicente E. Torres at the time of initial publication were incomplete and not aligned with the disclosure policy for the journal. The original and corrected disclosures are indicated in the table below.

View this table:

Table 1.

Corrected disclosures (corrections are bolded)

Footnotes

Published online ahead of print. Publication date available at www.cjasn.org.
See related editorial, “CJASN and Disclosure of Conflicts of Interest,” and Errata on pages 785–786 and 907–909, respectively.